Compare · AZN vs GRNA
AZN vs GRNA
Side-by-side comparison of AstraZeneca PLC (AZN) and GreenLight Biosciences Holdings PBC (GRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and GRNA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN carries a market cap of $262.48B.
- AZN has hit the wire 7 times in the past 4 weeks while GRNA has been quiet.
- AZN has more recent analyst coverage (25 ratings vs 2 for GRNA).
- Company
- AstraZeneca PLC
- GreenLight Biosciences Holdings PBC
- Price
- $169.00+0.41%
- $0.30-0.20%
- Market cap
- $262.48B
- -
- 1M return
- -7.41%
- -
- 1Y return
- -10.25%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2021
- News (4w)
- 7
- 0
- Recent ratings
- 25
- 2
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
GreenLight Biosciences Holdings PBC
GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.
Latest AZN
- Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest GRNA
- SEC Form 15-12G filed by GreenLight Biosciences Holdings PBC
- SEC Form SC 13D/A filed by GreenLight Biosciences Holdings PBC (Amendment)
- SEC Form SC 13D/A filed by GreenLight Biosciences Holdings PBC (Amendment)
- GreenLight Biosciences Holdings PBC filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (Amendment)
- SEC Form SC 13D/A filed by GreenLight Biosciences Holdings PBC (Amendment)
- SEC Form 4 filed by Kodiak Venture Partners Iii Lp
- SEC Form 3: New insider Kodiak Venture Partners Iii Lp claimed ownership of 9,809,895 shares
- SEC Form 4 filed by Clarke Dennis A.
- SEC Form 4 filed by Anderson Eric Senior
- SEC Form 4 filed by Cummings Foundation, Inc.